Related Experiment Video

Updated: Jun 15, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

mTOR pathway inhibition in renal cell carcinoma

Alvaro Pinto Marín1, Andrés Redondo Sánchez, Enrique Espinosa Arranz

  • 1Medical Oncology Department, University Hospital La Paz, Madrid, Spain. alvaro_pinto_marin@hotmail.com

Urologic Oncology
|March 9, 2010
PubMed

Insights

New agents have transformed renal cell carcinoma treatment, with mammalian target of rapamycin (mTOR) inhibitors like temsirolimus and everolimus showing significant efficacy in clinical trials for advanced disease.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) treatment has advanced significantly with new targeted therapies.
  • Cytokine therapy has been largely surpassed by newer agents.
  • Five new agents, including bevacizumab, sorafenib, sunitinib, temsirolimus, and everolimus, are now standard treatments.

Purpose of the Study:

  • To review the rationale behind mammalian target of rapamycin (mTOR) inhibition in renal cell carcinoma.
  • To discuss the clinical trial results of temsirolimus and everolimus in RCC treatment.

Main Methods:

  • Review of clinical trial data for mTOR inhibitors in RCC.
  • Analysis of efficacy and safety profiles of temsirolimus and everolimus.

Main Results:

  • mTOR inhibition has demonstrated efficacy in RCC, a first for this tumor type in phase III trials.
  • Temsirolimus is effective as first-line therapy for poor-prognosis patients.
  • Everolimus shows efficacy as second-line therapy after tyrosine-kinase inhibitor failure.

Conclusions:

  • Mammalian target of rapamycin (mTOR) inhibitors represent a significant advancement in renal cell carcinoma therapy.
  • Temsirolimus and everolimus offer effective treatment options for specific patient populations with advanced RCC.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...